Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
This study enrolls children with Autism Spectrum Disorder (ASD) and healthy children in a research study. The purpose of this study is to learn about how environmental factors can change the risk of ASD associated with genetic factors. Read More
Children ages 2-8 years old.
Children who have recently been diagnosed with Autism Spectrum Disorder OR generally healthy children.
Children are patients in participating clinics ( including the Autism Spectrum Disorder Center at Oishei Children’s Hospital, Oishei Children’s Hospital inpatient/outpatient clinics, or other UB affiliated participating general pediatric outpatie...
This study enrolls children less than 19 years old who are admitted to the Pediatric ICU and have tested positive for SARS-CoV2. The purpose of this study is to better understand the number of children who are in severe/critical care units due to COVID-19, risk factors, and factors that are associated with improved or worsening outcomes. Read More
Children ages 19 and under
Admitted to the Pediatric ICU or receiving treatment for severe case of COVID-19
Considered to have severe case of COVID-19
This study enrolls children and youths ages 10-18 who are planning an elective surgery for treatment of Crohn’s or Ulcerative Colitis. The purpose of this study is to see how everything goes before, during, and after your surgery. Read More
Youths ages 10-18
Diagnosis of Crohn's or Ulcerative Colitis and undergoing elective surgery treatment
This study enrolls adults and children who have had a recent kidney transplant. The purpose of this study is to improve outcomes after kidney donation and kidney transplantation by learning about how a specific gene may affect people. Read More
Adults or children who have undergone kidney transplantation or kidney donation.
Reside in US or Puerto Rico.
This study enrolls newborn infants with treatable retinopathy of prematurity (ROP). ROP is is one of the leading causes of childhood blindness worldwide. The purpose of this study is to learn if aflibercept (Eyelea) works to treat this condition. Read More
Children (newborn infants).
Gestational age at birth must be 32 weeks or less, birth weight must be 1500g or less
Must have retinopathy of prematurity (ROP) that has not yet been treated.
Must weigh at least 800 g
This is a single-center, randomized, open label, placebo controlled clinical trial. Patient who visit our ER and needs blood work or IV line placement may be eligible for the study. Subject enrolled in the study will have an equal chance to be assigned into one of the four study groups for pain relief during the needle stick, i.e. shot blocker, buzzy bee, vapocoolant, or placebo. Totally 220 subjects will be enrolled in the study, with 55 in each group. The PI hypothesizes that the Vapocoolant may not be as effective as the buzzy bee or shot blocker in pain relief. Read More
Children ages 6-18 years old.
Visiting ED at Oishei Children's Hospital and need blood work or IV line placement.
The purpose of the study is to learn about the safety and efficacy of a medication called TransCon CNP in children ages 2-10 with achondroplasia. Children with achondroplasia lack this compound which is instrumental in promoting growth and ameliorating other potential medical problems. Read More
Children ages 2-10 (inclusive).
Have a clinical diagnosis of ACH with genetic confirmation
Have not entered puberty yet.
Able to stand without assistance.
Caregiver willing and able to administer subcutaneous (under the skin) injections of study drug.
This study enrolls children and adults who have tested positive for COVID-19. The purpose of this study is to collect and bank blood samples of people who have COVID-19. We will analyze these samples to understand more about the virus. Read More
Adults or children
Positive for SARS-CoV-2 or highly suspicious for SARS-CoV-2 (symptoms with known contact).